Meclizine — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Motion sickness

• Scopolamine transdermal (availability varies)

Also listed for Vertigo

• Diazepam
• Dimenhydrinate
• Promethazine

Other medications in Neurological

• Memantine
• Midazolam Nasal
• Natalizumab (Neurology)
• Nusinersen
• Ocrelizumab
• Ofatumumab
• Oxcarbazepine
• Perampanel

About Meclizine

Feeling queasy or dizzy? Meclizine is a widely used medication that can offer relief from motion sickness, nausea, and vertigo. At TheDrugClub, we believe essential medications should be affordable and accessible. ### Meclizine: Your Ally Against Nausea and Dizziness

Meclizine is a medication often found in many medicine cabinets, praised for its effectiveness in combating motion sickness, nausea, and vertigo. Whether you're preparing for a long journey, prone to seasickness, or experiencing the disorienting spinning sensation of vertigo, meclizine offers a reliable solution to help you regain your balance and comfort. #### What It Treats

Primarily, meclizine is known for its ability to prevent and treat the symptoms associated with motion sickness, including nausea, vomiting, and dizziness. This makes it an invaluable companion for car rides, boat trips, flights, or any activity that might upset your inner ear. Beyond travel, it's also a key player in managing vertigo, a debilitating sensation of spinning or whirling. Conditions like Meniere's disease or certain inner ear disturbances can cause recurrent vertigo, and meclizine can provide significant relief, helping individuals maintain their daily activities with greater ease. #### How It Works

Meclizine belongs to a class of drugs known as antihistamines, but its mechanism for treating nausea and dizziness is distinct from its

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Meclizine is approved for (FDA label)

Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. Meclizine hydrochloride tablets are indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults ( 1 ).

Source: Read the full FDA label on DailyMed. Label effective date: August 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Meclizine (FDA label)

Meclizine Hydrochloride Tablets, USP are available containing 12.5 mg, 25 mg or 50 mg of meclizine dihydrochloride equivalent to 10.53 mg, 21.07 mg or 42.14 mg of meclizine free base, respectively. • The 12.5 mg tablets are a white to off-white 7.14 mm round, biconvex, beveled edge tablets debossed with 12 on one side of tablet and C on the other side of tablet. • The 25 mg tablets are a white to off-white 8.73 mm round, biconvex, beveled edge tablets debossed with 25 on one side of tablet and C on the other side of tablet.

Source: FDA prescribing information (DailyMed). Set ID: f755f8f3-7645-433c-b502-c1f15b700299. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Meclizine (FDA label)

The following adverse reactions associated with the use of meclizine hydrochloride were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported. Common adverse reactions are anaphylactic reaction, drowsiness, dry mouth, headache, fatigue, and vomiting. On rare occasions blurred vision has been reported ( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Source: FDA prescribing information (DailyMed). Set ID: f755f8f3-7645-433c-b502-c1f15b700299. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Meclizine (FDA label)

Meclizine hydrochloride tablets are contraindicated in patients with a hypersensitivity to meclizine or any of the inactive ingredients [see Adverse Reactions (6) and Description (11) ]. Meclizine hydrochloride tablets are contraindicated in patients with hypersensitivity to meclizine or any of the inactive ingredients ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: f755f8f3-7645-433c-b502-c1f15b700299. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Meclizine (FDA label)

• May cause drowsiness: Use caution when driving a car or operating dangerous machinery ( 5.1 ). • Potential anticholinergic action: this drug should be prescribed with care to patients with a history of asthma, glaucoma, or enlargement of the prostate gland ( 5.2 ). 5.1 Drowsiness Since drowsiness may occur with use of meclizine hydrochloride tablets, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery. Patients should avoid alcoholic beverages while taking meclizine hydrochloride tablets [see Drug Interactions (7.1) ] . 5.2 Concurrent Medical Conditions Because of its potential anticholinergic action, meclizine hydrochloride tablets should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

Source: FDA prescribing information (DailyMed). Set ID: f755f8f3-7645-433c-b502-c1f15b700299. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Meclizine (FDA label)

• Coadministration of meclizine hydrochloride tablets with other CNS depressants, including alcohol, may result in increased CNS depression ( 7.1 ). • CYP2D6 inhibitors: As meclizine is metabolized by CYP2D6, there is a potential for drug-drug interactions between meclizine hydrochloride tablets and CYP2D6 inhibitors ( 7.2 ). 7.1 CNS Depressants There may be increased CNS depression when meclizine hydrochloride tablets are administered concurrently with other CNS depressants, including alcohol [see Warnings and Precautions (5.1) ]. 7.2 CYP2D6 Inhibitors Based on in-vitro evaluation, meclizine is metabolized by CYP2D6. Therefore, there is a possibility for a drug interaction between meclizine hydrochloride tablets and CYP2D6 inhibitors. Therefore, monitor for adverse reactions and clinical effect accordingly.

Source: FDA prescribing information (DailyMed). Set ID: f755f8f3-7645-433c-b502-c1f15b700299. Label effective date: August 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.